{"id":78170,"date":"2026-09-02T15:13:27","date_gmt":"2026-09-02T07:13:27","guid":{"rendered":"https:\/\/flcube.com\/?p=78170"},"modified":"2026-09-02T15:13:28","modified_gmt":"2026-09-02T07:13:28","slug":"novartis-remibrutinib-beats-teriflunomide-in-phase-iii-remodel-trials-for-relapsing-multiple-sclerosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78170","title":{"rendered":"Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Novartis<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/NVS:NYSE\">NYSE: NVS<\/a>) announced positive topline results from its Phase III <strong>REMODEL-1\/-2<\/strong> clinical trials of <strong>remibrutinib<\/strong> in relapsing multiple sclerosis (RMS). The oral BTK inhibitor demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions, with a favorable safety profile.<\/p>\n\n\n\n<h2 id=\"h-regulatory-amp-development-background\" class=\"wp-block-heading\">Regulatory &amp; Development Background<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Agency<\/th><th>Event<\/th><th>Product<\/th><th>Indication<\/th><th>Date<\/th><\/tr><\/thead><tbody><tr><td><strong>US FDA<\/strong><\/td><td>Approval<\/td><td><strong>remibrutinib 25 mg<\/strong> (Rhapsido)<\/td><td>Chronic spontaneous urticaria (CSU) in adults<\/td><td>Sep 2025<\/td><\/tr><tr><td><strong>EMA<\/strong> (Europe)<\/td><td>Approval<\/td><td><strong>remibrutinib 25 mg<\/strong> (Rhapsido)<\/td><td>Chronic spontaneous urticaria (CSU) in adults<\/td><td>Apr 2026<\/td><\/tr><tr><td><strong>Novartis<\/strong> pipeline<\/td><td>Phase III topline results<\/td><td><strong>remibrutinib<\/strong><\/td><td>Relapsing multiple sclerosis (RMS)<\/td><td>01 Sep 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Discovered at <strong>Novartis<\/strong>, <strong>remibrutinib<\/strong> is currently being investigated in neuroscience indications \u2014 including the Phase III <strong>REMODEL<\/strong> trials in RMS and the <strong>REMASTER<\/strong> trial in secondary progressive multiple sclerosis (SPMS) \u2014 as well as other immune-mediated conditions such as hidradenitis suppurativa and food allergy.<\/p>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Remibrutinib, a highly selective, oral Bruton&#8217;s tyrosine kinase (BTK) inhibitor discovered at <strong>Novartis<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Blocks the BTK pathway, reducing activation of B cells and innate immune cells to modulate immune regulatory networks and related neuroinflammation<\/li>\n\n\n\n<li><strong>Route:<\/strong> Oral administration \u2014 a differentiator versus injectable disease-modifying therapies in multiple sclerosis<\/li>\n\n\n\n<li><strong>Established commercial footprint:<\/strong> Approved as <strong>Rhapsido<\/strong> (25 mg) in the US and Europe for chronic spontaneous urticaria (CSU)<\/li>\n\n\n\n<li><strong>Development breadth:<\/strong> Pipeline investigations span RMS, SPMS, hidradenitis suppurativa, and food allergy<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-remodel-1-2-topline\" class=\"wp-block-heading\">Clinical Evidence \u2013 REMODEL-1\/-2 (Topline)<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Comparator<\/th><th>Outcome<\/th><\/tr><\/thead><tbody><tr><td>Annualized relapse rate (ARR)<\/td><td>Teriflunomide<\/td><td><strong>Superiority demonstrated<\/strong><\/td><\/tr><tr><td>Inflammatory brain lesions<\/td><td>Teriflunomide<\/td><td><strong>Superior reduction<\/strong><\/td><\/tr><tr><td>Safety profile<\/td><td>\u2014<\/td><td><strong>Favorable<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">In the Phase III <strong>REMODEL-1<\/strong> and <strong>REMODEL-2<\/strong> studies, <strong>remibrutinib<\/strong> outperformed teriflunomide, an established oral standard of care in RMS, on both relapse reduction and suppression of inflammatory brain lesions \u2014 key markers of disease activity \u2014 while maintaining a favorable safety profile.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RMS franchise expansion:<\/strong> Positive <strong>REMODEL<\/strong> results position <strong>remibrutinib<\/strong> as a potential next-line oral disease-modifying therapy in the large RMS market<\/li>\n\n\n\n<li><strong>Differentiated mechanism:<\/strong> As a highly selective BTK inhibitor with effects on neuroinflammation, <strong>remibrutinib<\/strong> offers a mode of action distinct from existing RMS classes<\/li>\n\n\n\n<li><strong>Lifecycle potential:<\/strong> The CSU approval under the <strong>Rhapsido<\/strong> brand provides an existing revenue base while neuroscience indications could substantially enlarge the asset&#8217;s addressable market<\/li>\n\n\n\n<li><strong>Pipeline breadth:<\/strong> Ongoing trials including <strong>REMASTER<\/strong> in SPMS and studies in hidradenitis suppurativa and food allergy support a broad multi-indication trajectory<\/li>\n\n\n\n<li><strong>Sector signal:<\/strong> The readout reinforces BTK inhibition as an emerging competitive frontier in multiple sclerosis therapy<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief contains forward-looking statements regarding the clinical development, regulatory submissions, and commercial potential of remibrutinib. Actual results may differ materially due to clinical, regulatory, and market risks. This content is for informational purposes only and does not constitute investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novartis (NYSE: NVS) announced positive topline results from its Phase III REMODEL-1\/-2 clinical trials of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,140,865,24],"class_list":["post-78170","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-novartis","tag-nyse-nvs","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis (NYSE: NVS) announced positive topline results from its Phase III REMODEL-1\/-2 clinical trials of remibrutinib in relapsing multiple sclerosis (RMS). The oral BTK inhibitor demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions, with a favorable safety profile.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78170\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis\" \/>\n<meta property=\"og:description\" content=\"Novartis (NYSE: NVS) announced positive topline results from its Phase III REMODEL-1\/-2 clinical trials of remibrutinib in relapsing multiple sclerosis (RMS). The oral BTK inhibitor demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions, with a favorable safety profile.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78170\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-02T07:13:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-02T07:13:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78170#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78170\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis\",\"datePublished\":\"2026-09-02T07:13:27+00:00\",\"dateModified\":\"2026-09-02T07:13:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78170\"},\"wordCount\":452,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Novartis\",\"NYSE: NVS\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78170#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78170\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78170\",\"name\":\"Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-09-02T07:13:27+00:00\",\"dateModified\":\"2026-09-02T07:13:28+00:00\",\"description\":\"Novartis (NYSE: NVS) announced positive topline results from its Phase III REMODEL-1\\\/-2 clinical trials of remibrutinib in relapsing multiple sclerosis (RMS). The oral BTK inhibitor demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions, with a favorable safety profile.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78170#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78170\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78170#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis - Insight, China&#039;s Pharmaceutical Industry","description":"Novartis (NYSE: NVS) announced positive topline results from its Phase III REMODEL-1\/-2 clinical trials of remibrutinib in relapsing multiple sclerosis (RMS). The oral BTK inhibitor demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions, with a favorable safety profile.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78170","og_locale":"en_US","og_type":"article","og_title":"Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis","og_description":"Novartis (NYSE: NVS) announced positive topline results from its Phase III REMODEL-1\/-2 clinical trials of remibrutinib in relapsing multiple sclerosis (RMS). The oral BTK inhibitor demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions, with a favorable safety profile.","og_url":"https:\/\/flcube.com\/?p=78170","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-02T07:13:27+00:00","article_modified_time":"2026-09-02T07:13:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78170#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78170"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis","datePublished":"2026-09-02T07:13:27+00:00","dateModified":"2026-09-02T07:13:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78170"},"wordCount":452,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Novartis","NYSE: NVS","Rare \/ orphan disease drugs"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78170#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78170","url":"https:\/\/flcube.com\/?p=78170","name":"Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-09-02T07:13:27+00:00","dateModified":"2026-09-02T07:13:28+00:00","description":"Novartis (NYSE: NVS) announced positive topline results from its Phase III REMODEL-1\/-2 clinical trials of remibrutinib in relapsing multiple sclerosis (RMS). The oral BTK inhibitor demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions, with a favorable safety profile.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78170#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78170"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78170#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis Remibrutinib Beats Teriflunomide in Phase III REMODEL Trials for Relapsing Multiple Sclerosis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78170","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78170"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78170\/revisions"}],"predecessor-version":[{"id":78173,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78170\/revisions\/78173"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78170"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78170"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78170"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}